Published in Lab Business Week, April 24th, 2005
As previously announced, the notes were issued in a private placement in December 2004.
The company did not issue any new securities and will not receive any proceeds from the resale of securities under this registration statement.
The company's antibody development platform includes manufacturing capabilities that enable the rapid generation, selection and production of high affinity,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.